Premium lens technology closes the gap between cataract surgery and natural vision

Overview

For a decade, patients choosing premium lenses during cataract surgery have faced a trade-off: better range of vision, but dimmer, lower-contrast sight—especially in low light. On March 12, 2026, the Food and Drug Administration approved Johnson & Johnson's TECNIS PureSee, the first extended depth of focus lens cleared in the United States without a warning for loss of contrast sensitivity. In clinical trials, 97% of patients reported no bothersome visual disturbances like halos or glare.

That matters because roughly four million Americans undergo cataract surgery each year, and premium lenses—which reduce dependence on glasses—have been gaining ground rapidly, rising from 33% of global implantations in 2021 to 46% in 2024. A lens that extends the range of clear vision without the trade-offs that made many surgeons hesitate to recommend premium options could accelerate that shift further, reshaping a global market projected to reach $8 billion by 2035.

Play on this story Voices Debate Predict

Key Indicators

97%

Patients with no bothersome visual disturbances

In clinical trials, nearly all PureSee recipients reported no very bothersome halos, glare, or starbursts.

~4M

Annual U.S. cataract surgeries

Cataracts are the leading cause of vision loss globally, and the United States performs about four million procedures per year.

~500K

Eyes treated with PureSee worldwide

Nearly half a million eyes have already received the lens internationally since its 2024 launch outside the U.S.

46%

Global premium IOL adoption rate (2024)

Premium lenses now account for nearly half of all new implantations, up from 33% in 2021.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

People Involved

Tim Schmid

Leading J&J's medical device growth strategy, including vision

Organizations Involved

Johnson & Johnson Vision

Medical Device Manufacturer

Expanding premium IOL portfolio with three complementary lens platforms

Johnson & Johnson Vision manufactures the TECNIS platform of intraocular lenses and is one of the three dominant players in the global IOL market.

U.S. Food and Drug Administration

Federal regulatory agency

Approved PureSee without contrast sensitivity warning based on clinical data

The FDA regulates medical devices including intraocular lenses, reviewing clinical trial data to determine safety and labeling requirements before allowing U.S. sale.

Alcon

Medical Device Manufacturer

Leading IOL competitor with Vivity EDOF and PanOptix trifocal platforms

Alcon is the world's largest eye care device company and J&J Vision's primary competitor in the premium intraocular lens market.

Timeline

FDA approves first EDOF lens without contrast sensitivity warning
Regulatory

The FDA cleared Johnson & Johnson's TECNIS PureSee for the U.S. market, the first extended depth of focus intraocular lens approved without a warning for loss of contrast sensitivity. Nearly 500,000 eyes had already received the lens internationally. U.S. availability is expected later in 2026.
March 12th, 2026
J&J completes premium IOL trifecta with Odyssey approval
Regulatory

The FDA approved the TECNIS Odyssey, the first full visual range lens meeting new international standards. It reached 100,000 U.S. eyes within its first year, giving J&J a three-tier IOL lineup ahead of PureSee's U.S. entry.
October 1st, 2024
TECNIS PureSee launches internationally
Product Launch

Johnson & Johnson began selling the TECNIS PureSee in Europe, the Middle East, and Africa, following earlier launches in South Korea and New Zealand. The purely refractive lens design began accumulating real-world data outside clinical trials.
February 15th, 2024
Small-aperture IOL adds another approach to extended focus
Regulatory

The FDA approved the IC-8 Apthera from AcuFocus, a lens using a pinhole-like aperture to extend depth of focus. It offered a different optical principle but reduced light reaching the retina, limiting low-light performance.
July 22nd, 2022
J&J launches enhanced monofocal as mid-tier option
Product Launch

The FDA approved the TECNIS Eyhance, a monofocal lens with a modified surface that slightly extended depth of focus. It was the first monofocal design innovation in 20 years, offering 30% better image contrast in low light than competitors.
February 2nd, 2021
Alcon introduces non-diffractive EDOF approach
Regulatory

The FDA approved Alcon's Vivity, a non-diffractive extended depth of focus lens that stretched light rather than splitting it. Despite the new design, FDA labeling still warned of significant contrast sensitivity loss.
February 1st, 2020
First trifocal lens approved in the United States
Regulatory

The FDA approved Alcon's AcrySof IQ PanOptix, the first trifocal intraocular lens available in the U.S. It provided near, intermediate, and distance vision but used light-splitting optics that reduced contrast sensitivity.
August 27th, 2019
Johnson & Johnson acquires Abbott Medical Optics
Business

Johnson & Johnson completed its $4.3 billion acquisition of Abbott Medical Optics, gaining the TECNIS IOL platform and entering the premium lens market. The division was renamed Johnson & Johnson Vision.
February 27th, 2017
First extended depth of focus lens reaches U.S. market
Regulatory

The FDA approved Abbott Medical Optics' TECNIS Symfony, the first intraocular lens in a new category called extended depth of focus. It provided better intermediate vision than standard lenses but carried warnings about contrast sensitivity loss.
July 15th, 2016

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

Premium lenses become the default for most cataract patients

If the PureSee eliminates the primary objection surgeons have had about recommending premium lenses—contrast sensitivity loss—adoption could accelerate past the current 46% global share toward becoming the standard of care. Premium IOL adoption grew 37% between 2021 and 2024 even with the trade-offs. Removing that barrier, combined with an aging population driving cataract volumes higher, could push premium lenses past 60% adoption within a few years. The main constraint would be out-of-pocket cost, since most insurance covers only basic monofocal lenses.

Discussed by: Market research firms including Grand View Research and Precedence Research; industry analysts tracking the 33%-to-46% premium adoption trend

Consensus —

Competitors match the no-warning benchmark, sparking a quality race

Alcon, Bausch + Lomb, and other IOL manufacturers respond with next-generation designs that also eliminate contrast sensitivity warnings. This would shift the competitive battleground from 'premium versus monofocal' to differentiation within the premium tier—on factors like near vision quality, low-light performance, and tolerance for surgical imprecision. Patients would benefit from rapid improvement across all available options.

Discussed by: Ophthalmology Times and industry analysts covering Alcon's Vivity and pipeline lenses

Consensus —

Insurance and Medicare coverage expands to include premium lenses

As premium lenses demonstrate outcomes comparable to monofocal lenses on safety metrics while providing superior functional vision, pressure builds on Medicare and private insurers to cover them. Currently, patients pay $1,500 to $6,000 per eye out of pocket for premium lenses. A policy shift would dramatically expand access but would require evidence that the lenses reduce downstream costs like glasses prescriptions and falls linked to poor vision.

Discussed by: Health policy analysts and Medicare coverage watchers at U.S. News, Healthline

Consensus —

Real-world outcomes disappoint compared to clinical trials

Clinical trials are conducted under ideal conditions with carefully selected patients and experienced surgeons. If real-world PureSee outcomes in the broader U.S. market show higher rates of visual disturbances or less impressive contrast preservation than the 97% trial figure, it could slow adoption and invite regulatory scrutiny. The international track record of nearly 500,000 eyes makes this less likely but not impossible, since the U.S. patient population and surgical practices may differ.

Discussed by: Ophthalmology researchers publishing in peer-reviewed journals like Eye and the Journal of Refractive Surgery

Consensus —

Historical Context

The first intraocular lens implant (1949)

November 1949

What Happened

British ophthalmologist Harold Ridley implanted the first intraocular lens at St. Thomas' Hospital in London, after noticing that Royal Air Force pilots who got acrylic shards from shattered canopies lodged in their eyes did not reject the material. The medical establishment initially rejected the idea, and it took decades for IOL implantation to become standard practice.

Outcome

Short Term

Ridley faced professional ostracism and skepticism for years. Early lenses had high complication rates.

Long Term

Intraocular lens implantation became the standard of care for cataract surgery worldwide by the 1980s. The procedure is now the most commonly performed surgery in medicine.

Why It's Relevant Today

The PureSee approval is the latest step in a 77-year evolution from Ridley's improvised acrylic disc to precision-engineered refractive optics. Each generation has moved closer to replicating the natural lens's full capabilities.

LASIK approval transforms vision correction (1999)

1999-2005

What Happened

The FDA approved the first LASIK lasers in 1999, enabling refractive surgery that reshaped the cornea to correct nearsightedness, farsightedness, and astigmatism. Early LASIK patients frequently reported halos, glare, and reduced contrast sensitivity—the same complaints that plagued early premium IOLs.

Outcome

Short Term

LASIK adoption surged despite visual side effects, peaking at about 1.4 million procedures per year in the United States by 2007.

Long Term

Iterative improvements in laser technology and patient screening reduced side effects dramatically. Wavefront-guided LASIK now produces fewer visual disturbances than earlier generations, and the procedure remains widely popular.

Why It's Relevant Today

LASIK's trajectory illustrates how early-generation vision correction technologies carry visual side effects that improve with subsequent designs. The PureSee's elimination of the contrast sensitivity warning mirrors the refinement arc that LASIK followed over two decades, compressed into a single product generation.

AcrySof IQ PanOptix trifocal IOL approval (2019)

August 2019

What Happened

Alcon's PanOptix became the first trifocal intraocular lens approved in the United States, offering near, intermediate, and distance vision in a single lens. The light-splitting diffractive design provided the widest range of clear vision available at the time but came with the familiar trade-off: reduced contrast sensitivity and increased visual disturbances, particularly halos at night.

Outcome

Short Term

PanOptix rapidly gained market share, with Alcon reporting that over 99% of patients said they would choose the same lens again despite the side effects.

Long Term

The approval helped establish patient demand for glasses-free vision after cataract surgery and pushed competitors to develop lenses with fewer optical compromises.

Why It's Relevant Today

PanOptix demonstrated that patients were willing to accept some visual trade-offs for freedom from glasses. PureSee's clinical data suggests a new generation may no longer require that trade-off, potentially resetting patient expectations for what premium lenses should deliver.